AstraZeneca’s Bydureon BCise Receives EU approval Once-Weekly Prefilled Syringe for Type2 Diabetes
This approval is based on data from DURATION-NEO-1 enrolling 375 patients for duration of 28 wks and DURATION-NEO-2, showing its safety and efficacy
The study involves evaluation of Bydureon BCise IV qw, showing (reduction in HbA1c with 1.4% vs. 1.0% for Byetta BID IV for 28 wks.); (reduction in mean wt. 1.5 Kg vs. 1.9 Kg (baseline-97 Kg) in combination with oral antidiabetic medicines)
This new Bydureon BCise 2mg formulation qw has also received FDA approval in Oct 2017
Click here to read full press release/ article | Ref:AstraZeneca| Image: Pharma Boardroom
Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at email@example.com.